Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, ...
Examining protein changes in peripheral blood cells just 24 hours after initiating chemotherapy for acute myeloid leukemia (AML) could predict 5-year overall survival, potentially allowing treatment ...
Chimerix said today it will develop Cantex Pharmaceuticals’ Phase III-bound CX-01 as a first-line treatment for Acute Myeloid Leukemia (AML) and possibly other blood cancers, through an exclusive ...
Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...
Your bone marrow is supposed to be your body’s reliable blood cell factory, churning out healthy red cells, white cells, and platelets like clockwork. But sometimes this vital production system goes ...
Fate Therapeutics Inc (NASDAQ: FATE) has announced interim data from Phase 1 data from the Company's off-the-shelf, iPSC-derived natural killer (NK) cell programs in relapsed / refractory acute ...
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation ...
The refusal of blood transfusions by Jehovah’s Witnesses poses a major challenge in treating acute myeloid leukaemia (AML), ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback